TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00864500
Drug: Clobetasol Propionate 0.05% lotion, single exposure
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A: Experimental Subjects received Alpharma USPD, Inc formulated products
Study: NCT00634647
Drug: Satraplatin
Normalized name: Satraplatin
DrugBank: Satraplatin (DB04996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/m\^2 days 1-5 of every 35 day cycle
Study: NCT00634647
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg twice daily every 35 days
Study: NCT04293887
Drug: Recombinant human interferon α1β
Normalized name: Interferon beta, recombinant human
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
Study: NCT04257578
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03919175
Drug: Umbralisib
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
Study: NCT03919175
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
Study: NCT04031885
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT04031885
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered IM
Study: NCT02123407
Drug: Carbon Nanoparticles
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
Study: NCT03592472
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
Study: NCT03592472
Drug: Abexinostat
Normalized name: Abexinostat
DrugBank: Abexinostat (DB12565)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
Study: NCT01663272
Drug: CABOZANTINIB
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
Study: NCT01663272
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
Study: NCT04667819
Drug: Sodium Hyaluronate
Normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
Study: NCT00145509
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
Study: NCT02661438
Drug: Placebo to Ciprofloxacin DPI (BAYQ3939)
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
Study: NCT02922452
Drug: BMS-986141
Normalized name: BMS-986141
DrugBank: BMS-986141 (DB14942)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose BMS-986141 and Multiple doses of Dilitazem
Study: NCT01341184
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300 mg orally on days 20-41
Study: NCT01341184
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg orally on days 20-41
Study: NCT00394966
Drug: SCH 619734 Dose 1
Normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Study: NCT00394966
Drug: SCH 619734 Dose 2
Normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Study: NCT00394966
Drug: SCH 619734 Dose 3
Normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Study: NCT00394966
Drug: SCH 619734 Dose 4
Normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Study: NCT03909776
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
Study: NCT03354429
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
Study: NCT02285985
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets: 5 mg
Study: NCT04537806
Drug: Brexanolone
Normalized name: Brexanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as IV infusion.
Study: NCT02568488
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 850 mg orally twice daily for 6 months
Study: NCT02477020
Drug: TAK-063 20 mg
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-063 tablet.
Study: NCT02845271
Drug: fixed combination of paracetamol + tramadol hydrochloride
Normalized name: tramadol and paracetamol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02285751
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02285751
Drug: prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02285751
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03536728
Drug: DFMO
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
Study: NCT02566759
Drug: TAK-831 Oral Suspension
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-831 oral suspension.
Study: NCT02566759
Drug: TAK-831 Tablet
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-831 tablet.
Study: NCT01491321
Drug: Loxoprofen
Normalized name: Loxoprofen
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 60 mg/Tab, pers os 1Tab tid, for 3 weeks
Study: NCT00087568
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000/1200mg po bid for 36 or 60 weeks
Study: NCT00087568
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
Study: NCT01061060
Drug: Prostaglandin I2
Normalized name: Prostaglandin I2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00191321
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01034397
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
Study: NCT00963664
Drug: interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
Study: NCT01936961
Drug: CTLA-4 Antibody
Normalized name: Pd-1 x ctla-4 dual checkpoint inhibitor xmab20717
DrugBank: Vudalimab (DB18833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously over 90 minutes every 3 weeks for a total of four doses
Study: NCT01152723
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg, Single Dose
Study: NCT01264861
Drug: Safinamide
Normalized name: Safinamide
DrugBank: Safinamide (DB06654)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food.
Study: NCT02250885
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selective Inhibitor fo Nuclear Export (SINE)
Study: NCT02710630
Drug: Dabigatran etexilate tablet E1
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02710630
Drug: Dabigatran etexilate tablet D1
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02710630
Drug: Dabigatran etexilate tablet C1
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02710630
Drug: Dabigatran etexilate tablet B1
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02710630
Drug: Dabigatran etexilate tablet A1
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02710630
Drug: Dabigatran etexilate capsule
Normalized name: Dabigatran Etexilate Capsules
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02205892
Drug: Lupeol
Normalized name: Lupeol
DrugBank: Lupeol (DB12622)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
Study: NCT00873457
Drug: perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
Study: NCT01333774
Drug: Glucobay (Acarbose, BAYG5421)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study: NCT00252239
Drug: tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will compare 3 different doses of tenecteplase to tPA.
Study: NCT00252239
Drug: tissue plasminogen activator, tPA
DrugBank: Plasminogen (DB16701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
Study: NCT00004026
Drug: CT-2584
Normalized name: CT-2584
DrugBank: CT-2584 (DB13098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01930786
Drug: onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
Study: NCT04386876
Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH \& Co.-Germany)
Study: NCT02942654
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT01777945
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received docetaxel according to individualized physician-prescribed regimens.
Study: NCT03598751
Drug: BCD-085
Normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg / 2 mL subcutaneously
Study: NCT00813891
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
Study: NCT00813891
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
Study: NCT00813891
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
Study: NCT00238459
Drug: multiple licensed drugs not randomized
Normalized name: jojoba oil, randomized
DrugBank: Jojoba oil (DB14252)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04233814
Drug: Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
Normalized name: PPD
DrugBank: p-Phenylenediamine (DB14141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTI-03, a Caveolin-1 scaffold protein-derived 7-amino acid peptide to be administered as a dry powder by inhalation through a dry powder inhaler.
Study: NCT00113516
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
Study: NCT00113516
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
Study: NCT00113516
Drug: sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
Study: NCT00058305
Drug: bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00058305
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04203719
Drug: AK105
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
Study: NCT04203719
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a multi-target receptor tyrosine kinase inhibitor
Study: NCT03398993
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg twice daily from3rd day of cycle till 7th day of cycle
Study: NCT03398993
Drug: Human chorionic gonadotropin
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 IU dail;y from 6th day of cycle till 8th of cycle once daily
Study: NCT02579681
Drug: dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dimethyl fumarate administered as per the arm description
Study: NCT03652467
Drug: Deferoxamine and conventional TACE
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine is injected before conventional transarterial chemoembolization.
Study: NCT00982189
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to take lisinopril (active) or matching placebo pill once daily
Study: NCT02074735
Drug: Citicoline
Normalized name: Citicoline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
Study: NCT01337258
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dutasteride 0.5mg daily.
Study: NCT03669081
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin was administered orally: 75 mg 30 minutes prior to operation.
Study: NCT03669081
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
Study: NCT03217136
Drug: Ceftolozane/Tazobactam
Normalized name: CEFTOLOZANE/TAZOBACTAM
DrugBank: Tazobactam (DB01606)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftolozane 20 mg/kg (maximum 1 g) and tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days.
Study: NCT03217136
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants ≤ 28 days old, start with a loading dose of 15 mg/kg; then if ≤ 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if \> 2 kg are dosed 10 mg/kg every 8 hours.
Study: NCT03217136
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days.
Study: NCT03217136
Drug: Placebo for Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo for metronidazole administered IV every 8 hours for between 5 to 14 days.
Study: NCT03223103
Drug: Poly-ICLC
Normalized name: Poly-ICLC
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-ICLC 100mcg per peptide per dose
Study: NCT00578773
Drug: Moxifloxacin otic solution
Normalized name: moxifloxacin Ophthalmic Solution
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study: NCT01789216
Drug: NSAID
Normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01789216
Drug: Gabapentinoids
Normalized name: Gabapentinoids
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03041363
Drug: Triheptanoin
Normalized name: Triheptanoin
DrugBank: Triheptanoin (DB11677)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triheptanoin will be administered for 7 days 4 times daily.
Study: NCT01365624
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
Study: NCT01732913
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
Study: NCT01732913
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg tablets administered orally twice daily
Study: NCT00304005
Drug: laromustine
Normalized name: Laromustine
DrugBank: Laromustine (DB05817)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04166318
Drug: Mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00046345
Drug: Atazanavir (BMS-232632)
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no